| scholarly article | Q13442814 |
| P50 | author | Dimitri P Mikhailidis | Q62561943 |
| Efstathios D Pagourelias | Q89509499 | ||
| P2093 | author name string | Konstantinos Tziomalos | |
| Asterios Karagiannis | |||
| Eleni Theocharidou | |||
| Thomas D Gossios | |||
| Vasilios G Athyros | |||
| Panagiotis Anagnostis | |||
| Niki Katsiki | |||
| GREACE Study Collaborative Group | |||
| Eygenia Gkaliagkousi | |||
| P2860 | cites work | Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) | Q27860959 |
| MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial | Q28214393 | ||
| Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization | Q28283679 | ||
| Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial | Q29617817 | ||
| Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels | Q29620696 | ||
| Clinical features and natural history of nonalcoholic steatosis syndromes | Q34215131 | ||
| Epidemiology of cardiovascular disease in chronic renal disease | Q34302341 | ||
| Smoking diminishes the beneficial effect of statins: observations from the landmark trials | Q34380222 | ||
| Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment | Q35029623 | ||
| Effects of statin medication on mortality risk associated with type 2 diabetes in older persons: the population-based AGES-Reykjavik Study | Q35320148 | ||
| The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. | Q35587723 | ||
| Markers of kidney function in the elderly in relation to the new CKD-EPI formula for estimation of glomerular filtration rate | Q35674278 | ||
| Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study | Q35674320 | ||
| IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis | Q35691372 | ||
| Lipids, blood pressure, kidney - what was new in 2011? | Q35691396 | ||
| Patient with hypertriglyceridemia, type 2 diabetes, and chronic kidney disease treated with atorvastatin and omega-3 Fatty Acid ethyl esters | Q36310496 | ||
| The epidemiology of nonalcoholic fatty liver disease in adults | Q36422726 | ||
| GI epidemiology: nonalcoholic fatty liver disease | Q36777903 | ||
| Statin therapy in the elderly: a review | Q37393348 | ||
| Lipid-lowering drug therapy in elderly patients. | Q37854791 | ||
| Hyperuricaemia: more than just a cause of gout? | Q38049115 | ||
| Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. | Q38447369 | ||
| Is serum uric acid level an independent predictor of heart failure among patients with coronary artery disease? | Q39482033 | ||
| Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis | Q42791977 | ||
| Cardiovascular benefit of magnitude of low-density lipoprotein cholesterol reduction: a comparison of subgroups by age. | Q43270045 | ||
| In patients with chronic stable angina, secondary prevention appears better in the very old compared to younger patients: the Coronary Artery Disease in gENeral practiCE (CADENCE) Substudy. | Q43495227 | ||
| Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study | Q44086403 | ||
| Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study | Q44118533 | ||
| Level of kidney function as a risk factor for cardiovascular outcomes in the elderly | Q44358496 | ||
| Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome | Q44385945 | ||
| Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus | Q44687349 | ||
| Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study | Q44813339 | ||
| Uric acid levels and vascular disease | Q44939381 | ||
| Atherosclerotic risk factors and renal function in the elderly: the role of hyperfibrinogenaemia and smoking. Results from the Italian Longitudinal Study on Ageing (ILSA). | Q45168727 | ||
| Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study | Q45383571 | ||
| Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study | Q45389074 | ||
| Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study | Q46778720 | ||
| Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study | Q46945399 | ||
| Serum uric acid as an independent predictor of early death after acute stroke | Q48128078 | ||
| Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. | Q51366717 | ||
| Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. | Q51497896 | ||
| Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? | Q51724036 | ||
| Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. | Q52230212 | ||
| Serum uric acid. Its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia | Q54019206 | ||
| Prevalence and Correlates of Elevated Serum Creatinine Levels | Q57740595 | ||
| Serum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study | Q57740599 | ||
| Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? | Q58149661 | ||
| Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease | Q61070320 | ||
| Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey | Q73801429 | ||
| Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S) | Q73994857 | ||
| Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease | Q77456395 | ||
| Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients | Q78555962 | ||
| Statins and renal function. Is the compound and dose making a difference? | Q79665672 | ||
| Statins for non-alcoholic fatty liver disease: a new indication? | Q80109515 | ||
| Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options | Q83219314 | ||
| Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome | Q83227340 | ||
| Pharmacotherapy: statins and new-onset diabetes mellitus--a matter for debate | Q83396492 | ||
| Elevated serum uric acid is an independent predictor for cardiovascular events in patients with severe coronary artery stenosis: subanalysis of the Japanese Coronary Artery Disease (JCAD) Study | Q83592216 | ||
| Smoking and non-alcoholic steatohepatitis (NASH): the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial | Q83619714 | ||
| Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study | Q83862765 | ||
| Statins in patients with renal dysfunction | Q84040152 | ||
| Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study | Q84468684 | ||
| The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study | Q85403601 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | coronary artery disease | Q844935 |
| P304 | page(s) | 418-426 | |
| P577 | publication date | 2013-05-28 | |
| P1433 | published in | Archives of Medical Science | Q15753010 |
| P1476 | title | Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study | |
| P478 | volume | 9 |
| Q36958257 | Adding carotid total plaque area to the Framingham risk score improves cardiovascular risk classification. |
| Q38631018 | Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options |
| Q35163413 | Danqi Pill regulates lipid metabolism disorder induced by myocardial ischemia through FATP-CPTI pathway |
| Q36418976 | Ear lobe crease: a marker of coronary artery disease? |
| Q39012176 | Effect of statins on serum vitamin D concentrations: a systematic review and meta-analysis |
| Q36197338 | GPs' perspectives on secondary cardiovascular prevention in older age: a focus group study in the Netherlands |
| Q41952419 | Heart function disturbances in chronic kidney disease - echocardiographic indices |
| Q35062506 | High levels of LDL-C combined with low levels of HDL-C further increase platelet activation in hypercholesterolemic patients |
| Q33574532 | Lipid, blood pressure and kidney update 2013. |
| Q26771550 | Lipids, blood pressure and kidney update 2015 |
| Q37701904 | Management and risk factor control of coronary artery disease in elderly versus nonelderly: a multicenter registry |
| Q35992108 | Objectives and methodology of Romanian SEPHAR II Survey. Project for comparing the prevalence and control of cardiovascular risk factors in two East-European countries: Romania and Poland. |
| Q51243305 | Older statin initiators in Finland - cardiovascular risk profiles and persistence of use. |
| Q92475652 | Pharmacological Treatment for Non-alcoholic Fatty Liver Disease |
| Q44800910 | Protective role of statins in patients with acute coronary syndrome aged ≥ 75 years with low LDL-C who underwent percutaneous coronary intervention |
| Q35232279 | Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel |
| Q37180162 | Statin treatment in the elderly: how much do we know? |
| Q39085748 | The Relationship Between Hemodialysis and the Echocardiographic Findings in Patients with Chronic Kidney Disease |
Search more.